<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30028088</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>06</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1742-4658</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>285</Volume>
            <Issue>19</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>The FEBS journal</Title>
          <ISOAbbreviation>FEBS J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Determinants of dopaminergic neuron loss in Parkinson's disease.</ArticleTitle>
        <Pagination>
          <StartPage>3657</StartPage>
          <EndPage>3668</EndPage>
          <MedlinePgn>3657-3668</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.14607</ELocationID>
        <Abstract>
          <AbstractText>The cardinal motor symptoms of Parkinson's disease (PD) are caused by the death of dopaminergic neurons in the substantia nigra pars compacta (SNc). Alpha-synuclein (aSYN) pathology and mitochondrial dysfunction have been implicated in PD pathogenesis, but until recently it was unclear why SNc dopaminergic neurons should be particularly vulnerable to these two types of insult. In this brief review, the evidence that SNc dopaminergic neurons have an anatomical, physiological, and biochemical phenotype that predisposes them to mitochondrial dysfunction and synuclein pathology is summarized. The recognition that certain traits may predispose neurons to PD-linked pathology creates translational opportunities for slowing or stopping disease progression.</AbstractText>
          <CopyrightInformation>© 2018 Federation of European Biochemical Societies.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Surmeier</LastName>
            <ForeName>Dalton James</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P50 NS047085</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>NS047085</GrantID>
            <Acronym>GF</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>08</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>FEBS J</MedlineTA>
        <NlmUniqueID>101229646</NlmUniqueID>
        <ISSNLinking>1742-464X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">autophagy</Keyword>
        <Keyword MajorTopicYN="Y">axon</Keyword>
        <Keyword MajorTopicYN="Y">bioenergetics</Keyword>
        <Keyword MajorTopicYN="Y">calcium</Keyword>
        <Keyword MajorTopicYN="Y">dopamin</Keyword>
        <Keyword MajorTopicYN="Y">lewy pathology</Keyword>
        <Keyword MajorTopicYN="Y">mitochondria</Keyword>
        <Keyword MajorTopicYN="Y">synuclein</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30028088</ArticleId>
        <ArticleId IdType="mid">NIHMS982631</ArticleId>
        <ArticleId IdType="pmc">PMC6546423</ArticleId>
        <ArticleId IdType="doi">10.1111/febs.14607</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>de Lau LM &amp; Breteler MM (2006) Epidemiology of Parkinson’s disease, Lancet Neurol
5, 525–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16713924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bach JP, Riedel O, Klotsche J, Spottke A, Dodel R &amp; Wittchen HU (2012) Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson’s disease, J Neurol Sci
314, 41–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22133477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A &amp; Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology
68, 384–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17082464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S &amp; Lenhart G (2005) Burden of illness in Parkinson’s disease, Mov Disord
20, 1449–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16007641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorsey ER, George BP, Leff B &amp; Willis AW (2013) The coming crisis: obtaining care for the growing burden of neurodegenerative conditions, Neurology
80, 1989–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3716348</ArticleId>
            <ArticleId IdType="pubmed">23616157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agarwal HK, Zhai S, Surmeier DJ &amp; Ellis-Davies GCR (2017) Intracellular Uncaging of cGMP with Blue Light, ACS Chem Neurosci
8, 2139–2144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5647252</ArticleId>
            <ArticleId IdType="pubmed">28762726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE &amp; Lang AE (2017) Parkinson disease, Nat Rev Dis Primers
3, 17013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28332488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H, Ghebremedhin E, Rub U, Bratzke H &amp; Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology, Cell Tissue Res
318, 121–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15338272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surmeier DJ, Obeso JA &amp; Halliday GM (2017) Selective neuronal vulnerability in Parkinson disease, Nat Rev Neurosci
18, 101–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5564322</ArticleId>
            <ArticleId IdType="pubmed">28104909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goedert M, Spillantini MG, Del Tredici K &amp; Braak H (2013) 100 years of Lewy pathology, Nat Rev Neurol
9, 13–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23183883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iljina M, Garcia GA, Horrocks MH, Tosatto L, Choi ML, Ganzinger KA, Abramov AY, Gandhi S, Wood NW, Cremades N, Dobson CM, Knowles TP &amp; Klenerman D (2016) Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading, Proc Natl Acad Sci U S A
113, E1206–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4780632</ArticleId>
            <ArticleId IdType="pubmed">26884195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts HL &amp; Brown DR (2015) Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein., Biomolecules
5, 282–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4496673</ArticleId>
            <ArticleId IdType="pubmed">25816357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poulopoulos M, Levy OA &amp; Alcalay RN (2012) The neuropathology of genetic Parkinson&amp;apos;s disease., Movement disorders : official journal of the Movement Disorder Society
27, 831–842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3383342</ArticleId>
            <ArticleId IdType="pubmed">22451330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konno T, Ross OA, Puschmann A, Dickson DW &amp; Wszolek ZK (2016) Autosomal dominant Parkinson&amp;apos;s disease caused by SNCA duplications., Parkinsonism &amp; related disorders
22
Suppl 1, S1–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4820832</ArticleId>
            <ArticleId IdType="pubmed">26350119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawkes CH, Del Tredici K &amp; Braak H (2007) Parkinson’s disease: a dual-hit hypothesis, Neuropathol Appl Neurobiol
33, 599–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7194308</ArticleId>
            <ArticleId IdType="pubmed">17961138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brundin P &amp; Melki R (2017) Prying into the Prion Hypothesis for Parkinson’s Disease, J Neurosci
37, 9808–9818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5637113</ArticleId>
            <ArticleId IdType="pubmed">29021298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O &amp; Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation, Nat Med
14, 501–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18391963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kordower JH, Chu Y, Hauser RA, Freeman TB &amp; Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease, Nat Med
14, 504–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18391962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ &amp; Lee VM (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science
338, 949–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3552321</ArticleId>
            <ArticleId IdType="pubmed">23161999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DMA &amp; Hasegawa M (2013) Prion-like spreading of pathological α-synuclein in brain., Brain : a journal of neurology
136, 1128–1138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3613715</ArticleId>
            <ArticleId IdType="pubmed">23466394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Recasens A, Dehay B, Bové J, Carballo Carbajal I, Dovero S, Pérez Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bezard E &amp; Vila M (2014) Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys, Annals of neurology
75, 351–362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24243558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, Kang HC, Zhang J, Xu J, Chen R, Park H, Andrabi SA, Kang SU, Goncalves RA, Liang Y, Zhang S, Qi C, Lam S, Keiler JA, Tyson J, Kim D, Panicker N, Yun SP, Workman CJ, Vignali DA, Dawson VL, Ko HS &amp; Dawson TM (2016) Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3, Science
353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5510615</ArticleId>
            <ArticleId IdType="pubmed">27708076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrivastava AN, Redeker V, Fritz N, Pieri L, Almeida LG, Spolidoro M, Liebmann T, Bousset L, Renner M, Lena C, Aperia A, Melki R &amp; Triller A (2015) alpha-synuclein assemblies sequester neuronal alpha3-Na+/K+-ATPase and impair Na+ gradient, EMBO J
34, 2408–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4601662</ArticleId>
            <ArticleId IdType="pubmed">26323479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchihara T &amp; Giasson BI (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies., Acta neuropathologica
131, 49–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4698305</ArticleId>
            <ArticleId IdType="pubmed">26446103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walsh DM &amp; Selkoe DJ (2016) A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration, Nature reviews Neuroscience
17, 251–260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6701169</ArticleId>
            <ArticleId IdType="pubmed">26988744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacino AN, Brooks MM, Chakrabarty P, Saha K, Khoshbouei H, Golde TE &amp; Giasson BI (2017) Proteolysis of alpha-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology, J Neurochem
140, 662–678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5452425</ArticleId>
            <ArticleId IdType="pubmed">27424880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H &amp; Del Tredici K (2017) Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff, J Parkinsons Dis
7, S73–S87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5345633</ArticleId>
            <ArticleId IdType="pubmed">28282810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts HL &amp; Brown DR (2015) Seeking a mechanism for the toxicity of oligomeric alpha-synuclein, Biomolecules
5, 282–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4496673</ArticleId>
            <ArticleId IdType="pubmed">25816357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Trejo-Morales M, Gerez J, Picotti P, Jensen PH, Campioni S, Riek R, Winkler J, Gage FH, Winner B &amp; Masliah E (2014) Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo, Brain
137, 1496–513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3999721</ArticleId>
            <ArticleId IdType="pubmed">24662516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C &amp; Lee MK (2012) Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo, J Neurosci
32, 3301–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3548448</ArticleId>
            <ArticleId IdType="pubmed">22399752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH &amp; Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic, Proc Natl Acad Sci U S A
108, 4194–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3053976</ArticleId>
            <ArticleId IdType="pubmed">21325059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helwig M, Klinkenberg M, Rusconi R, Musgrove RE, Majbour NK, El-Agnaf OM, Ulusoy A &amp; Di Monte DA (2016) Brain propagation of transduced alpha-synuclein involves non-fibrillar protein species and is enhanced in alpha-synuclein null mice, Brain
139, 856–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26719384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulusoy A, Musgrove RE, Rusconi R, Klinkenberg M, Helwig M, Schneider A &amp; Di Monte DA (2015) Neuron-to-neuron alpha-synuclein propagation in vivo is independent of neuronal injury, Acta Neuropathol Commun
3, 13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4369863</ArticleId>
            <ArticleId IdType="pubmed">25853980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dauer W &amp; Przedborski S (2003) Parkinson’s disease: mechanisms and models, Neuron
39, 889–909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12971891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schapira AH (2011) Mitochondrial pathology in Parkinson’s disease, Mt Sinai J Med
78, 872–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22069211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haelterman NA, Yoon WH, Sandoval H, Jaiswal M, Shulman JM &amp; Bellen HJ (2014) A mitocentric view of Parkinson’s disease, Annu Rev Neurosci
37, 137–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4659514</ArticleId>
            <ArticleId IdType="pubmed">24821430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beilina A &amp; Cookson MR (2016) Genes associated with Parkinson’s disease: regulation of autophagy and beyond, J Neurochem
139
Suppl 1, 91–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5834228</ArticleId>
            <ArticleId IdType="pubmed">26223426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cookson MR (2010) DJ-1, PINK1, and their effects on mitochondrial pathways, Mov Disord
25
Suppl 1, S44–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840196</ArticleId>
            <ArticleId IdType="pubmed">20187230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heo JY, Park JH, Kim SJ, Seo KS, Han JS, Lee SH, Kim JM, Park JI, Park SK, Lim K, Hwang BD, Shong M &amp; Kweon GR (2012) DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: involvement of mitochondrial complex I assembly, PLoS One
7, e32629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3293835</ArticleId>
            <ArticleId IdType="pubmed">22403686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Funayama M &amp; Hattori N (2015) CHCHD2 and Parkinson’s disease--authors’ reply, Lancet Neurol
14, 682–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26067115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenamyre JT, Cannon JR, Drolet R &amp; Mastroberardino PG (2010) Lessons from the rotenone model of Parkinson’s disease, Trends Pharmacol Sci
31, 141–2; author reply 142–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846992</ArticleId>
            <ArticleId IdType="pubmed">20096940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Przedborski S, Tieu K, Perier C &amp; Vila M (2004) MPTP as a mitochondrial neurotoxic model of Parkinson’s disease, J Bioenerg Biomembr
36, 375–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15377875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB &amp; Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease, Lancet
1, 1269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2566813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grunewald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M &amp; Turnbull DM (2016) Mitochondrial DNA Depletion in Respiratory Chain-Deficient Parkinson Disease Neurons, Ann Neurol
79, 366–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4819690</ArticleId>
            <ArticleId IdType="pubmed">26605748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW &amp; Turnbull DM (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease, Nat Genet
38, 515–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16604074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bender A, Schwarzkopf RM, McMillan A, Krishnan KJ, Rieder G, Neumann M, Elstner M, Turnbull DM &amp; Klopstock T (2008) Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions, J Neurol
255, 1231–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18604467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW &amp; Khrapko K (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons, Nat Genet
38, 518–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16604072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R &amp; Kaneko T (2009) Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum, J Neurosci
29, 444–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6664950</ArticleId>
            <ArticleId IdType="pubmed">19144844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolam JP &amp; Pissadaki EK (2012) Living on the edge with too many mouths to feed: why dopamine neurons die, Mov Disord
27, 1478–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3504389</ArticleId>
            <ArticleId IdType="pubmed">23008164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunn BHM, Cragg SJ, Bolam JP, Spillantini MG &amp; Wade-Martins R (2015) Impaired intracellular trafficking defines early Parkinson&amp;apos;s disease., Trends in neurosciences
38, 178–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4740565</ArticleId>
            <ArticleId IdType="pubmed">25639775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pacelli C, Giguère N, Bourque M-J, Lévesque M, Slack RS &amp; Trudeau L-E (2015) Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons., Current biology : CB
25, 2349–2360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26320949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT &amp; Burton EA (2015) shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson’s disease model, J Clin Invest
125, 2721–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4563670</ArticleId>
            <ArticleId IdType="pubmed">26075822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou F-M, Wilson CJ &amp; Dani JA (2002) Cholinergic interneuron characteristics and nicotinic properties in the striatum, J Neurobiol
53, 590–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12436423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bean BP (2007) The action potential in mammalian central neurons, Nat Rev Neurosci
8, 451–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17514198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT &amp; Surmeier DJ (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1, Nature
468, 696–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4465557</ArticleId>
            <ArticleId IdType="pubmed">21068725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nedergaard S, Flatman JA &amp; Engberg I (1993) Nifedipine- and omega-conotoxin-sensitive Ca2+ conductances in guinea-pig substantia nigra pars compacta neurones, J Physiol
466, 727–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1175500</ArticleId>
            <ArticleId IdType="pubmed">8410714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puopolo M, Raviola E &amp; Bean BP (2007) Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons, J Neurosci
27, 645–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6672803</ArticleId>
            <ArticleId IdType="pubmed">17234596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morikawa H &amp; Paladini CA (2011) Dynamic regulation of midbrain dopamine neuron activity: intrinsic, synaptic, and plasticity mechanisms, Neuroscience
198, 95–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3221882</ArticleId>
            <ArticleId IdType="pubmed">21872647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foehring RC, Zhang XF, Lee JC &amp; Callaway JC (2009) Endogenous calcium buffering capacity of substantia nigral dopamine neurons, J Neurophysiol
102, 2326–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2775382</ArticleId>
            <ArticleId IdType="pubmed">19675297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaliq ZM &amp; Bean BP (2010) Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances, J Neurosci
30, 7401–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2892804</ArticleId>
            <ArticleId IdType="pubmed">20505107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzman JN, Sanchez-Padilla J, Chan CS &amp; Surmeier DJ (2009) Robust pacemaking in substantia nigra dopaminergic neurons, J Neurosci
29, 11011–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2784968</ArticleId>
            <ArticleId IdType="pubmed">19726659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE &amp; Surmeier DJ (2007) ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease, Nature
447, 1081–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17558391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Philippart F, Destreel G, Merino-Sepulveda P, Henny P, Engel D &amp; Seutin V (2016) Differential Somatic Ca2+ Channel Profile in Midbrain Dopaminergic Neurons, J Neurosci
36, 7234–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6705535</ArticleId>
            <ArticleId IdType="pubmed">27383597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Putzier I, Kullmann PH, Horn JP &amp; Levitan ES (2009) Cav1.3 channel voltage dependence, not Ca2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons, J Neurosci
29, 15414–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796195</ArticleId>
            <ArticleId IdType="pubmed">20007466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi T, Rizzuto R, Hajnoczky G &amp; Su TP (2009) MAM: more than just a housekeeper, Trends Cell Biol
19, 81–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2750097</ArticleId>
            <ArticleId IdType="pubmed">19144519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balaban RS (2009) The role of Ca(2+) signaling in the coordination of mitochondrial ATP production with cardiac work, Biochim Biophys Acta
1787, 1334–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3177847</ArticleId>
            <ArticleId IdType="pubmed">19481532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholls DG &amp; Budd SL (1998) Mitochondria and neuronal glutamate excitotoxicity, Biochim Biophys Acta
1366, 97–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9714760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dragicevic E, Schiemann J &amp; Liss B (2015) Dopamine midbrain neurons in health and Parkinson’s disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels, Neuroscience
284, 798–814.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Votyakova TV &amp; Reynolds IJ (2001) DeltaPsi(m)-Dependent and -independent production of reactive oxygen species by rat brain mitochondria, J Neurochem
79, 266–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11677254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reeve A, Simcox E &amp; Turnbull D (2014) Ageing and Parkinson’s disease: why is advancing age the biggest risk factor?, Ageing Res Rev
14, 19–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3989046</ArticleId>
            <ArticleId IdType="pubmed">24503004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gegg ME &amp; Schapira AH (2016) Mitochondrial dysfunction associated with glucocerebrosidase deficiency, Neurobiol Dis
90, 43–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4838669</ArticleId>
            <ArticleId IdType="pubmed">26388395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A, Dawson VL &amp; Dawson TM (2008) What causes cell death in Parkinson’s disease?, Ann Neurol
64
Suppl 2, S3–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4118469</ArticleId>
            <ArticleId IdType="pubmed">19127586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong E &amp; Cuervo AM (2010) Autophagy gone awry in neurodegenerative diseases, Nat Neurosci
13, 805–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4038747</ArticleId>
            <ArticleId IdType="pubmed">20581817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzman JN, Ilijic E, Yang B, Sanchez-Padilla J, Wokosin D, Galtieri D, Kondapalli J, Schumacker PT &amp; Surmeier DJ (2018) Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress, J Clin Invest
128, 2266–2280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5983329</ArticleId>
            <ArticleId IdType="pubmed">29708514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rcom-H’cheo-Gauthier A, Goodwin J &amp; Pountney DL (2014) Interactions between calcium and alpha-synuclein in neurodegeneration, Biomolecules
4, 795–811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4192672</ArticleId>
            <ArticleId IdType="pubmed">25256602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nath S, Goodwin J, Engelborghs Y &amp; Pountney DL (2011) Raised calcium promotes α-synuclein aggregate formation, Molecular and Cellular Neuroscience
46, 516–526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21145971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lautenschlager J, Stephens AD, Fusco G, Strohl F, Curry N, Zacharopoulou M, Michel CH, Laine R, Nespovitaya N, Fantham M, Pinotsi D, Zago W, Fraser P, Tandon A, St George-Hyslop P, Rees E, Phillips JJ, De Simone A, Kaminski CF &amp; Schierle GSK (2018) C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction, Nat Commun
9, 712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5818535</ArticleId>
            <ArticleId IdType="pubmed">29459792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diepenbroek M, Casadei N, Esmer H, Saido TC, Takano J, Kahle PJ, Nixon RA, Rao MV, Melki R, Pieri L, Helling S, Marcus K, Krueger R, Masliah E, Riess O &amp; Nuber S (2014) Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]alphaSyn transgenic mice, Hum Mol Genet
23, 3975–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4110482</ArticleId>
            <ArticleId IdType="pubmed">24619358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E &amp; Rohn TT (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation, Am J Pathol
170, 1725–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1854966</ArticleId>
            <ArticleId IdType="pubmed">17456777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melachroinou K, Xilouri M, Emmanouilidou E, Masgrau R, Papazafiri P, Stefanis L &amp; Vekrellis K (2013) Deregulation of calcium homeostasis mediates secreted α-synuclein-induced neurotoxicity., Neurobiology of aging
34, 2853–2865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23891486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caraveo G, Auluck PK, Whitesell L, Chung CY, Baru V, Mosharov EV, Yan X, Ben-Johny M, Soste M, Picotti P, Kim H, Caldwell KA, Caldwell GA, Sulzer D, Yue DT &amp; Lindquist S (2014) Calcineurin determines toxic versus beneficial responses to alpha-synuclein, Proc Natl Acad Sci U S A
111, E3544–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4151770</ArticleId>
            <ArticleId IdType="pubmed">25122673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gómez-Sintes R, Ledesma MD &amp; Boya P (2016) Lysosomal cell death mechanisms in aging., Ageing research reviews </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26947122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angelova PR, Ludtmann MH, Horrocks MH, Negoda A, Cremades N, Klenerman D, Dobson CM, Wood NW, Pavlov EV, Gandhi S &amp; Abramov AY (2016) Ca2+ is a key factor in alpha-synuclein-induced neurotoxicity, J Cell Sci
129, 1792–801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4893653</ArticleId>
            <ArticleId IdType="pubmed">26989132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M &amp; Oertel WH (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level, Brain Res
741, 185–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9001722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilijic E, Guzman JN &amp; Surmeier DJ (2011) The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease, Neurobiol Dis
43, 364–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3235730</ArticleId>
            <ArticleId IdType="pubmed">21515375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Verma P, Balaji G, Samantaray S &amp; Mohanakumar KP (2016) Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice, Neurochem Int
99, 221–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27395789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marras C, Gruneir A, Rochon P, Wang X, Anderson G, Brotchie J, Bell CM, Fox S &amp; Austin PC (2012) Dihydropyridine calcium channel blockers and the progression of parkinsonism, Ann Neurol
71, 362–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22451203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M &amp; Hviid A (2012) Use of calcium channel blockers and Parkinson’s disease, Am J Epidemiol
175, 627–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22387374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH &amp; Friis S (2010) L-type calcium channel blockers and Parkinson disease in Denmark, Ann Neurol
67, 600–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917467</ArticleId>
            <ArticleId IdType="pubmed">20437557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gudala K, Kanukula R &amp; Bansal D (2015) Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-Analysis, Int J Chronic Dis
2015, 697404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4590944</ArticleId>
            <ArticleId IdType="pubmed">26464872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee YC, Lin CH, Wu RM, Lin JW, Chang CH &amp; Lai MS (2014) Antihypertensive agents and risk of Parkinson’s disease: a nationwide cohort study, PLoS One
9, e98961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4049613</ArticleId>
            <ArticleId IdType="pubmed">24910980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Becker C, Jick SS &amp; Meier CR (2008) Use of antihypertensives and the risk of Parkinson disease, Neurology
70, 1438–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18256367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez M, Rodriguez-Sabate C, Morales I, Sanchez A &amp; Sabate M (2015) Parkinson’s disease as a result of aging, Aging Cell
14, 293–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4406659</ArticleId>
            <ArticleId IdType="pubmed">25677794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duda J, Potschke C &amp; Liss B (2016) Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson’s disease, J Neurochem
139
Suppl 1, 156–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5095868</ArticleId>
            <ArticleId IdType="pubmed">26865375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calì T, Ottolini D &amp; Brini M (2014) Calcium signaling in Parkinson&amp;apos;s disease., Cell and tissue research
357, 439–454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24781149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surmeier DJ, Guzman JN, Sanchez J &amp; Schumacker PT (2012) Physiological phenotype and vulnerability in Parkinson’s disease, Cold Spring Harb Perspect Med
2, a009290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3385938</ArticleId>
            <ArticleId IdType="pubmed">22762023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulzer D (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease, Trends Neurosci
30, 244–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17418429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Williams EA &amp; Zahm DS (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases, Neurotoxicology
25, 101–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14697885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hastings TG (2009) The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease, J Bioenerg Biomembr
41, 469–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19967436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Kruger R, Surmeier DJ &amp; Krainc D (2017) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease, Science
357, 1255–1261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6021018</ArticleId>
            <ArticleId IdType="pubmed">28882997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plotegher N &amp; Duchen MR (2017) Crosstalk between Lysosomes and Mitochondria in Parkinson’s Disease, Front Cell Dev Biol
5, 110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5732996</ArticleId>
            <ArticleId IdType="pubmed">29312935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH &amp; Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons, Neuron
62, 218–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2677560</ArticleId>
            <ArticleId IdType="pubmed">19409267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain MK &amp; Bhat R (2014) Modulation of human alpha-synuclein aggregation by a combined effect of calcium and dopamine, Neurobiol Dis
63, 115–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24269918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brimblecombe KR, Gracie CJ, Platt NJ &amp; Cragg SJ (2015) Gating of dopamine transmission by calcium and axonal N-, Q-, T- and L-type voltage-gated calcium channels differs between striatal domains, J Physiol
593, 929–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4398530</ArticleId>
            <ArticleId IdType="pubmed">25533038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong YC &amp; Krainc D (2017) alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies, Nat Med
23, 1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28170377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abeliovich A &amp; Gitler AD (2016) Defects in trafficking bridge Parkinson’s disease pathology and genetics, Nature
539, 207–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27830778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorenberg EL &amp; Chandra SS (2017) The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease, Front Neurosci
11, 248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5437171</ArticleId>
            <ArticleId IdType="pubmed">28579939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirola L, Behari M, Shishir C &amp; Thelma BK (2016) Identification of a novel homozygous mutation Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile Parkinsonism, Parkinsonism Relat Disord
31, 124–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27496670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen KH, Wu RM, Lin HI, Tai CH &amp; Lin CH (2015) Mutational analysis of SYNJ1 gene (PARK20) in Parkinson’s disease in a Taiwanese population,
Neurobiol Aging
36, 2905
e7–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26149920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drouet V &amp; Lesage S (2014) Synaptojanin 1 mutation in Parkinson’s disease brings further insight into the neuropathological mechanisms, Biomed Res Int
2014, 289728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4181773</ArticleId>
            <ArticleId IdType="pubmed">25302295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsayed LE, Drouet V, Usenko T, Mohammed IN, Hamed AA, Elseed MA, Salih MA, Koko ME, Mohamed AY, Siddig RA, Elbashir MI, Ibrahim ME, Durr A, Stevanin G, Lesage S, Ahmed AE &amp; Brice A (2016) A Novel Nonsense Mutation in DNAJC6 Expands the Phenotype of Autosomal-Recessive Juvenile-Onset Parkinson’s Disease, Ann Neurol
79, 335–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26703368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benazzouz A, Piallat B, Ni ZG, Koudsie A, Pollak P &amp; Benabid AL (2000) Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson’s disease, Cell Transplant
9, 215–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10811394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez MC, Obeso JA &amp; Olanow CW (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotection, Ann Neurol
44, S175–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9749591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beal MF (1998) Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis, Ann Neurol
44, S110–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9749581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace BA, Ashkan K, Heise CE, Foote KD, Torres N, Mitrofanis J &amp; Benabid AL (2007) Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys, Brain
130, 2129–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17584773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Temel Y, Visser-Vandewalle V, Kaplan S, Kozan R, Daemen MA, Blokland A, Schmitz C &amp; Steinbusch HW (2006) Protection of nigral cell death by bilateral subthalamic nucleus stimulation, Brain Res
1120, 100–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16999940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takada M, Matsumura M, Kojima J, Yamaji Y, Inase M, Tokuno H, Nambu A &amp; Imai H (2000) Protection against dopaminergic nigrostriatal cell death by excitatory input ablation, Eur J Neurosci
12, 1771–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10792454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meredith GE, Totterdell S, Beales M &amp; Meshul CK (2009) Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson’s disease, Exp Neurol
219, 334–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2728791</ArticleId>
            <ArticleId IdType="pubmed">19523952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Breit S, Bouali-Benazzouz R, Benabid AL &amp; Benazzouz A (2001) Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal activity of the pedunculopontine nucleus, which is reversed by the lesion of the subthalamic nucleus in the rat, Eur J Neurosci
14, 1833–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11860479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scarnati E, Campana E &amp; Pacitti C (1984) Pedunculopontine-evoked excitation of substantia nigra neurons in the rat, Brain Res
304, 351–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6744046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galtieri DJ, Estep CM, Wokosin DL, Traynelis S &amp; Surmeier DJ (2017) Pedunculopontine glutamatergic neurons control spike patterning in substantia nigra dopaminergic neurons, Elife
6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5643088</ArticleId>
            <ArticleId IdType="pubmed">28980939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Futami T, Takakusaki K &amp; Kitai ST (1995) Glutamatergic and cholinergic inputs from the pedunculopontine tegmental nucleus to dopamine neurons in the substantia nigra pars compacta, Neurosci Res
21, 331–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7777224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng X, Xie J, Wang X, Wang X, Zhang X, Hou Y, Lei C, Li M, Qu Q, He T, Han H, Yao X &amp; Wang M (2016) Altered neuronal activity in the pedunculopontine nucleus: An electrophysiological study in a rat model of Parkinson’s disease, Behav Brain Res
305, 57–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26924016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang QJ, Liu J, Wang Y, Wang S, Wu ZH, Yan W, Hui YP &amp; Ali U (2008) The firing activity of presumed cholinergic and non-cholinergic neurons of the pedunculopontine nucleus in 6-hydroxydopamine-lesioned rats: an in vivo electrophysiological study, Brain Res
1243, 152–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18824158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V &amp; Eidelberg D (2007) Changes in network activity with the progression of Parkinson’s disease, Brain
130, 1834–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4454378</ArticleId>
            <ArticleId IdType="pubmed">17470495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernon AC, Zbarsky V, Datla KP, Croucher MJ &amp; Dexter DT (2007) Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo, J Neurochem
103, 1075–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17714448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Litim N, Morissette M &amp; Di Paolo T (2017) Metabotropic glutamate receptors as therapeutic targets in Parkinson’s disease: An update from the last 5 years of research, Neuropharmacology
115, 166–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27055772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T &amp; Smith Y (2011) Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys, Brain
134, 2057–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3122374</ArticleId>
            <ArticleId IdType="pubmed">21705423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reeve AK, Ludtmann MH, Angelova PR, Simcox EM, Horrocks MH, Klenerman D, Gandhi S, Turnbull DM &amp; Abramov AY (2015) Aggregated alpha-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons, Cell Death Dis
6, e1820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4650719</ArticleId>
            <ArticleId IdType="pubmed">26181201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luth ES, Stavrovskaya IG, Bartels T, Kristal BS &amp; Selkoe DJ (2014) Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction, J Biol Chem
289, 21490–507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4118111</ArticleId>
            <ArticleId IdType="pubmed">24942732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abramov AY, Berezhnov AV, Fedotova EI, Zinchenko VP &amp; Dolgacheva LP (2017) Interaction of misfolded proteins and mitochondria in neurodegenerative disorders, Biochem Soc Trans </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28733489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dryanovski DI, Guzman JN, Xie Z, Galteri DJ, Volpicelli-Daley LA, Lee VM, Miller RJ, Schumacker PT &amp; Surmeier DJ (2013) Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons, J Neurosci
33, 10154–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3682382</ArticleId>
            <ArticleId IdType="pubmed">23761910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guardia-Laguarta C, Area-Gomez E, Schon EA &amp; Przedborski S (2015) A new role for alpha-synuclein in Parkinson’s disease: Alteration of ER-mitochondrial communication, Mov Disord
30, 1026–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25952565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramaniam M, Althof D, Gispert S, Schwenk J, Auburger G, Kulik A, Fakler B &amp; Roeper J (2014) Mutant alpha-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels, J Neurosci
34, 13586–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6608377</ArticleId>
            <ArticleId IdType="pubmed">25297088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zucca FA, Segura-Aguilar J, Ferrari E, Munoz P, Paris I, Sulzer D, Sarna T, Casella L &amp; Zecca L (2017) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease, Prog Neurobiol
155, 96–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4826627</ArticleId>
            <ArticleId IdType="pubmed">26455458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collier TJ, Kanaan NM &amp; Kordower JH (2017) Aging and Parkinson’s disease: Different sides of the same coin?, Mov Disord
32, 983–990.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5844262</ArticleId>
            <ArticleId IdType="pubmed">28520211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirkwood TB (2010) Global aging and the brain, Nutr Rev
68
Suppl 2, S65–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21091950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahin E &amp; DePinho RA (2012) Axis of ageing: telomeres, p53 and mitochondria, Nat Rev Mol Cell Biol
13, 397–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3718675</ArticleId>
            <ArticleId IdType="pubmed">22588366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thakur P, Breger LS, Lundblad M, Wan OW, Mattsson B, Luk KC, Lee VMY, Trojanowski JQ &amp; Bjorklund A (2017) Modeling Parkinson’s disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain, Proc Natl Acad Sci U S A
114, E8284–E8293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5625925</ArticleId>
            <ArticleId IdType="pubmed">28900002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ &amp; Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions, Science
290, 985–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11062131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burke RE &amp; O’Malley K (2013) Axon degeneration in Parkinson’s disease, Exp Neurol
246, 72–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3340476</ArticleId>
            <ArticleId IdType="pubmed">22285449</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
